Regulation FD Disclosure
Show detailsHide details
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
Celcuity Inc.
Could not find a ticker for this position, may be a filing error
A clinical-stage biotech developing gedatolisib, a drug aimed at blocking cancer-driving cell signals to treat advanced breast and prostate cancer. Founded in 2012 by Brian Sullivan and Lance Laing, the company first built CELsignia, a tool that reads living tumor cells, before pivoting to drug development. Its name blends "cell" and "acuity" — a nod to the sharp, precise view the founders wanted of a tumor's inner workings.
Celcuity Inc 2.75% Convertible Bond due 2031
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits